Overactive bladder/enuresis:

Indications for: VESICARE LS

Treatment of neurogenic detrusor overactivity in pediatric patients.

Adult Dosage:

Not applicable.

Children Dosage:

<2yrs: not established. Take once daily, followed by liquid (eg, water or milk). Base dose on body wt. ≥2yrs: 9–15kg: initially 2mL (max 4mL); >15–30kg: initially 3mL (max 5mL); >30–45kg: initially 3mL (max 6mL); >45–60kg: initially 4mL (max 8mL); >60kg: initially 5mL (max 10mL). Severe renal impairment (CrCl <30mL/min/1.73m2), moderate hepatic impairment (Child-Pugh B), or concomitant strong CYP3A4 inhibitors: do not exceed the recommended initial dose.

VESICARE LS Contraindications:

For tabs: urinary retention. For tabs & susp: gastric retention, uncontrolled narrow-angle glaucoma.

VESICARE LS Warnings/Precautions:

Significant bladder outlet obstruction, decreased GI motility, high risk or history of QT prolongation, severe hepatic impairment (Child-Pugh C): not recommended. Controlled narrow-angle glaucoma. Monitor for CNS effects esp. after initiation or dose increases; consider dose reduction or discontinuation if occurs. Severe renal or moderate hepatic impairment. Pregnancy. Nursing mothers.

See Also:

VESICARE LS Classification:

Muscarinic antagonist.

VESICARE LS Interactions:

Potentiated by strong CYP3A4 inhibitors (eg, ketoconazole). May be antagonized by CYP3A4 inducers. Avoid drugs known to prolong the QT interval. Additive anticholinergic effects with other anticholinergics.

Adverse Reactions:

Dry mouth, constipation, UTI, blurred vision; CNS effects (eg, headache, confusion, hallucination, somnolence); angioedema and anaphylactic reactions (discontinue if occurs).

Generic Drug Availability:


How Supplied:

Tabs—30, 90; Susp—150mL